The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

German independent research institute BioMed X announces the successful completion of its oncology research project in ...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.

Highlights,Citigroup revised its price target for Merck & Co., adjusting it from $125 to $115 while maintaining an optimistic ...

BioMed X, a German independent research institute, announces the successful completion of its oncology research project in ...